Pioglitazone may exhibit beneficial and adverse effects on cybrid cells carrying the variant m.3243A>G

Josef Finsterer, MD, PhD*, Carla A. Scorza, Fulvio A. Scorza, MD

Pioglitazone may exhibit beneficial and adverse effects on cybrid cells carrying the variant m.3243A>G

Josef Finsterer, MD, PhD*, Carla A. Scorza, Fulvio A. Scorza, MD

Cite this:

[1]

Josef Finsterer, MD, PhD*, Carla A. Scorza, Fulvio A. Scorza, MD, “Pioglitazone may exhibit beneficial and adverse effects on cybrid cells carrying the variant m.3243A>G”, ijmhs, vol. 10, no. 06, pp. 922–923, Jun. 2020.

RIGHTS & PERMISSIONS

Article Views

262

Altmetric

Citations

LEARN ABOUT THESE METRICS

Abstract

With interest we read the article by Burgin et al. about a
study on the effect of the p eroxisome proliferator-activated
receptor (PPAR) activator pioglitazone together with deoxyribonucleosides
on ATP production in cybrid cells. containing
>90% of the m.3243A>G mutation [1].The authors
found that pioglitazone increased mtDNA copy number,
oxygen Konsumption rate, and mitochondrial mass in cybrid
cells and controls but did not affect cell proliferation
[1]. Pioglitazone decreased the number of mtDNA
encoded transcripts, further reducing the already reduced
transcript levels [1]. Pioglitazone did not increase the
steady state levels of mature respiratory chain complexes
[1]. We have the following comments and concerns.

Content

Part of special issue:

Innovative Journal of Medical and Health Science

Article Metrics by Journal Systems

Citations not available
Readers 262
Download 130

Altmetric Attention score:

Altmetric badge

Share this article

Source

How to Cite

[1]

Issue Vol. 10 No. 06 (2020): Innovative Journal of Medical and Health Science
Section Research Articles

License

All paper submissions must carry the following duly signed by all the authors:
â€œI certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.â€

Innovative Journal of Medical and Health Sciences

Pioglitazone may exhibit beneficial and adverse effects on cybrid cells carrying the variant m.3243A>G

Article Views

Altmetric

Citations

Abstract

Special Issue

Article Metrics Graph

Content

Section

Source

License

Most read articles by the same author(s)